Parallax Volatility Advisers
AIMT

Parallax Volatility Advisers’s Aimmune Therapeutics AIMT Stock Holding History

Parallax Volatility Advisers’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,442
Closed -$291K – 3402
2020
Q3 		$291K Buy
+8,442
New +$180K ﹤0.01% 2417
2020
Q1 		– Sell
-22,551
Closed -$755K – 2886
2019
Q4 		$755K Buy
+22,551
New +$630K ﹤0.01% 1608
2019
Q1 		– Sell
-141
Closed -$3.32K – 4433
2018
Q4 		$3K Buy
+141
New +$3.65K ﹤0.01% 2661
2018
Q3 		– Sell
-8,072
Closed -$228K – 3929
2018
Q2 		$217K Buy
8,072
+6,372
+375% +$195K ﹤0.01% 1393
2018
Q1 		$54K Sell
1,700
-3,634
-68% -$128K ﹤0.01% 1517
2017
Q4 		$202K Buy
+5,334
New +$172K ﹤0.01% 2284

Parallax Volatility Advisers's AIMT Position: Q4 2020 in Review

Parallax Volatility Advisers sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 8,442 shares — an estimated $291K sold.

Parallax Volatility Advisers first reported a position in AIMT in Q4 2017 and held it in 6 quarters. The position peaked at $755K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Parallax Volatility Advisers reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parallax Volatility Advisers sold 8,442 Aimmune Therapeutics shares in Q4 2020, an estimated $291K.
  • Parallax Volatility Advisers first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 6 quarters.
  • Parallax Volatility Advisers's Aimmune Therapeutics position peaked at $755K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Parallax Volatility Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.